What is the optimal treatment for a 42‑year‑old man with a 12 cm non‑seminomatous germ‑cell testicular tumor composed of 85 % embryonal carcinoma, who has undergone radical orchiectomy and has a persistently elevated alpha‑fetoprotein level of 22 ng/mL?

Treatment Recommendation for Stage IS Non-Seminomatous Germ Cell Tumor with Elevated AFP

This patient requires systemic chemotherapy with 3 cycles of BEP (bleomycin, etoposide, cisplatin) as first-line treatment, given the persistently elevated AFP indicating systemic disease despite the absence of radiographic metastases. 1

Clinical Staging and Risk Stratification

This 42-year-old male has Stage IS disease, defined by persistently elevated tumor markers (AFP = 22 ng/mL) after orchiectomy without radiographic evidence of metastatic disease 1. The large tumor size (12 cm) and high embryonal carcinoma component (85%) are additional high-risk features 1, 2.

Key Diagnostic Considerations:

• AFP elevation (22 ng/mL) after orchiectomy indicates occult metastatic disease 3, 4. The half-life of AFP is 5-7 days 1, so persistent elevation beyond expected normalization timeframes confirms active disease.
• Stage IS classification requires: normal imaging but persistently elevated or rising tumor markers post-orchiectomy 1
• The 85% embryonal carcinoma component is a high-risk histologic feature associated with increased relapse rates (40-50%) 1

Treatment Algorithm

Primary Treatment: Systemic Chemotherapy

Administer 3 cycles of BEP chemotherapy (bleomycin 30 mg on days 1,8,15; etoposide 100 mg/m² on days 1-5; cisplatin 20 mg/m² on days 1-5, repeated every 3 weeks) 1. This regimen is indicated because:

• Elevated tumor markers after orchiectomy indicate systemic disease requiring chemotherapy, not surgery 3. A landmark study showed that all 11 patients with marker-only elevation who underwent initial retroperitoneal lymph node dissection (RPLND) subsequently required chemotherapy anyway, whereas only 1 of 4 who received primary chemotherapy needed later surgery 3.
• The IGCCCG good prognosis classification applies (non-mediastinal primary, AFP <1000 ng/mL, no non-pulmonary visceral metastases) 1, warranting 3 cycles of BEP as standard treatment 1.
• Four cycles of EP (etoposide/cisplatin) without bleomycin is an alternative only if contraindications to bleomycin exist 1, but there is no indication to avoid bleomycin in this case.

Why Not Surgery or Surveillance?

• RPLND is inappropriate for Stage IS disease 1, 3. Elevated markers indicate systemic disease beyond the retroperitoneum, making regional surgery inadequate 3, 4.
• Surveillance is contraindicated once markers are elevated post-orchiectomy 1. The elevated AFP confirms active disease requiring immediate treatment.
• Adjuvant chemotherapy (2 cycles BEP) is only for Stage I disease with normal markers 1, not for Stage IS with persistent elevation.

Post-Chemotherapy Management

Monitoring Protocol:

• Repeat tumor markers and imaging 4-8 weeks after completing chemotherapy 1. Obtain chest X-ray and CT scan of abdomen/pelvis at initial metastatic sites 1.
• Complete response is defined as normal tumor markers AND no residual masses or retroperitoneal lymph nodes ≥10 mm 1.
• If residual lymph nodes exceed 10 mm after chemotherapy with normalized markers, perform nerve-sparing RPLND 1. Residual masses may contain mature teratoma (chemotherapy-resistant) requiring surgical excision 1.

Risk Stratification for Recurrence:

The patient's high-risk features include:

• Large tumor size (12 cm)
• High embryonal carcinoma component (85%) 2, 5
• Lymphovascular invasion (if present on pathology) 1, 2

These features historically conferred 40-50% relapse risk in Stage I disease 1, but with appropriate chemotherapy for Stage IS, cure rates exceed 95% 1.

Critical Pitfalls to Avoid

1. Do not perform RPLND as initial treatment for marker-positive disease 3. This approach universally fails, requiring subsequent chemotherapy anyway while exposing the patient to unnecessary surgery and its complications (6-8% risk of retrograde ejaculation) 1.

2. Do not delay treatment waiting for markers to rise further 1. AFP of 22 ng/mL (above normal of 8-20 ng/mL depending on laboratory) after appropriate post-orchiectomy observation period confirms active disease 1, 4.

3. Do not undertreate with only 2 cycles of BEP 1. Two cycles are reserved for adjuvant treatment in Stage I disease with normal markers 1, not for Stage IS with marker elevation indicating metastatic disease.

4. Ensure proper IGCCCG risk classification 1, 6. This patient qualifies as good prognosis (3 cycles BEP), not intermediate/poor prognosis (4 cycles BEP), based on AFP <1000 ng/mL, non-mediastinal primary, and absence of non-pulmonary visceral metastases 1.

Expected Outcomes

With appropriate 3-cycle BEP chemotherapy, this patient has:

• >95% cure rate 1
• 89-96% 5-year progression-free survival for good prognosis NSGCT 6
• Minimal long-term toxicity with 3 cycles compared to more intensive regimens 7